---
title: "Ensysce Biosciences, Inc. (ENSC.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ENSC.US.md"
symbol: "ENSC.US"
name: "Ensysce Biosciences, Inc."
industry: "生物技术"
---

# Ensysce Biosciences, Inc. (ENSC.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.ensysce.com](https://www.ensysce.com) |

## Company Profile

Ensysce Biosciences, Inc.是一家临床阶段的制药公司，专注于开发用于缓解美国严重疼痛的处方药，特别是针对阿片类药物的误用、滥用和过量。该公司利用胰蛋白酶激活的滥用保护（TAAP）平台开发产品，该平台旨在仅在特定生理条件下释放临床有效药物；以及多药滥用抵抗（MPAR）平台，这是一种过量保护的阿片类前药技术。公司的主要产品候选药物是 PF614，这是一种 TAAP 羟考酮前药，旨在治疗严重或慢性疼痛；以及 PF614-MPAR，这是 PF614 和纳法莫斯塔特的组合产品，用于过量保护。该公司还在开发 PF8001 和 PF8026，这两种是用于注意力缺陷多动障碍的安非他命的延...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:15.000Z

**Overall: D (0.66)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 335 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.51% |  |
| Net Profit YoY | -38.42% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.18 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.41M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 4.49M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -270.54% | E |
| Profit Margin | -244.49% | E |
| Gross Margin | -499.25% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1.51% | C |
| Net Profit YoY | -38.42% | D |
| Total Assets YoY | -66.12% | E |
| Net Assets YoY | -86.71% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -40.90% | D |
| OCF YoY | 1.51% | C |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.71 | B |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 72.49% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Ensysce Biosciences, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-270.54%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-244.49%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-499.25%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1.51%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-38.42%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-66.12%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-86.71%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-40.90%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "1.51%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.71",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "72.49%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 艾伯维 (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.13 | 88/603 | - | - | - |
| PB | 1.18 | 102/603 | 2.38 | 1.71 | 1.11 |
| PS (TTM) | 0.32 | 6/603 | 0.97 | 0.83 | 0.58 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-08T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.39 |
| Highest Target | 16.45 |
| Lowest Target | 16.45 |

## References

- [Company Overview](https://longbridge.com/en/quote/ENSC.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ENSC.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ENSC.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.